Interest of belatacept as a non-nephrotoxic immunosuppressive treatment in cardiac transplant patients at risk of chronic renal failure.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516541-40-00

Acronym

RC19_0133

Enrollment

Registered

2024-09-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early graft dysfunction after heart transplant

Brief summary

Determination of plasma creatinine and calculation of clearance according to the formula CKD EPI at M3 and M12 post HT.

Detailed description

- Myocardial biopsies between M3 and M12 post HT, - Anti-HLA antibody testing according to the habits of heart transplant centres, - Fasting blood glucose and HBA1C at M3 and M12 post HT, - Death, - Number of dialysis sessions between M3 and M12 post HT

Interventions

DRUGPROGRAF 5 mg capsule

DRUGNeoral 100 mg Soft Capsules

DRUGAdvagraf 5 mg prolonged-release hard capsules

DRUGNULOJIX 250 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Determination of plasma creatinine and calculation of clearance according to the formula CKD EPI at M3 and M12 post HT.	—

Secondary

Measure	Time frame
- Myocardial biopsies between M3 and M12 post HT, - Anti-HLA antibody testing according to the habits of heart transplant centres, - Fasting blood glucose and HBA1C at M3 and M12 post HT, - Death, - Number of dialysis sessions between M3 and M12 post HT	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026